![]() |
市場調査レポート
商品コード
1394215
グルタチオン樹脂の世界市場の評価:包装タイプ別、用途別、地域別、機会、予測(2016年~2030年)Glutathione Resin Market Assessment, By Packaging Type [Less Than 50 ml, 50-100 ml, Greater Than 100 ml], By Application [Protein Purification, Laboratories Research, Others], By Region, Opportunities and Forecast, 2016-2030F |
||||||
カスタマイズ可能
|
グルタチオン樹脂の世界市場の評価:包装タイプ別、用途別、地域別、機会、予測(2016年~2030年) |
出版日: 2023年12月08日
発行: Market Xcel - Markets and Data
ページ情報: 英文 205 Pages
納期: 3~5営業日
|
世界のグルタチオン樹脂の市場規模は、2022年の4億5,130万米ドルから2030年に7億9,290万米ドルに達し、2023年~2030年の予測期間にCAGRで7.3%の成長が見込まれています。
グルタチオン化合物をアガロースビーズに適切な数の原子スペーサーで結合させ、精製中の障害効果を低減させる、費用対効果の高いタンパク質の精製プロセスに向けたソリューションが頻繁に検討されています。このような費用対効果の高い化合物の開発に向けた技術革新は加速しており、各社がこの分野で研究を進めています。Thermo Fisher Scientific Inc.は、グルタチオン化合物を12原子のスペーサーを介してアガロースビーズに連結し、立体障害を実質的に最小化するPierceグルタチオンの開発に成功しました。
同社は、FPLCデリバリー用途向けに、プレパックされたクロマトグラフィカートリッジでPierceグルタチオンアガロース製品を提供しています。この製品は、細胞溶解液からGSTタグ付き融合タンパク質をアフィニティ精製するための高い性能と能力を提供します。Pierceグルタチオン樹脂は経済的な価格で、精製性能と結合能を損なうことなく5回使用することができ、費用対効果の高い製品となっています。この製品は、同社の細胞溶解試薬と併用して、哺乳類やバクテリアの細胞培養物から抽出および精製できることが臨床的に検証されています。
COVID-19の発生は、すべての人が感染症にかかりやすくなり、多数の部門と人々の生活に深刻な影響を与えました。製薬研究への投資の減少に伴う研究所の閉鎖は、経済の安定性を悪化させました。しかし、COVID-19に対抗する効果的な薬剤を開発する緊急性は、障害効果を低減しながらグルタチオン-S-トランスフェラーゼ(GST)タグ付き組換えタンパク質の迅速な精製を組み込むグルタチオン樹脂に複数の機会を生み出しました。パンデミックの状況は、市場が拡大し、企業がサービスを取り入れるための大きな可能性を生み出しています。
グルタチオン樹脂市場は、先進の最適化されたタンパク質精製プロセスに対する需要の増加に伴い、順調に成長しています。Cytivaは、グルタチオン-S-トランスフェラーゼ(GST)タグ付きタンパク質のバッチ精製を行うためのアフィニティクロマトグラフィ樹脂であるGlutathione Sepharose 4B製品を開発し、高い結合能を達成しました。このグルタチオン樹脂は、一般的に使用されるすべての水性緩衝液に対して化学的に安定であり、タンパク質間相互作用の研究に広く使用されています。
当レポートでは、世界のグルタチオン樹脂市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。
Global glutathione resin market size was valued at USD 451.3 million in 2022, which is expected to reach USD 792.9 million in 2030, with a CAGR of 7.3% for the forecast period between 2023 and 2030.
Protein purification processes are successively achieved using affinity chromatography, which offers high selectivity, resolution, and capacity in much less time. An effective design affinity chromatography, glutathione resin is a one-step purification process used for recombinant glutathione S-transferase (GST) fusion proteins and relevant binding proteins in insect cells, E. coli, and mammalian cells. Glutathione resin is widely considered an excellent compound for high-performance purifications, especially when high binding capacity is required for batch purification. Elevated glutathione (GSH) levels are significantly observed in several types of cancer cells that increase antioxidant capacity.
Glutathione affinity resins are designed to purify glutathione-S-transferase (GST)-tagged recombinant proteins rapidly. High binding capacity and yield of glutathione-S-transferase (GST) fusion proteins of 5-8 mg/ml settled resin is successfully developed by Merck KGaA, Darmstadt. Also, biological companies are successfully researching to develop cost-effective purification processes while reducing hinderance effect.
Glutathione is an essential compound that increases the immune system and provides a barrier to harmful diseases prone to humans. The rapid purification of glutathione-binding proteins from yeast, insect, bacteria, and glutathione-S-transferase (GST)-tagged recombinant proteins are accomplished by simply designing glutathione affinity resin.
The glutathione ligand is coupled to highly cross-linked 4% agarose beads to optimize and provide high binding capacity for GST-tagged proteins. Flow dependent characteristics is associated with binding of GST to glutathione and lower flow rates usually enhancing the binding capacity.
Merck KGaA, Darmstadt has introduced the trademark product GST. Bind Resins utilize a 14-atom spacer arm to covalently attach reduced glutathione by using sulfide linkage. The yield of glutathione-S-transferase (GST) fusion proteins of 5-8 mg/ml settled resin are achieved by a high degree substation of glutathione, ensuring high binding capacity. In November 2022, LTS Lohmann, a prominent producer of needle-free drug delivery systems, especially transdermal patches, had an investment of USD 14 million with the Global Health Investment Corporation. In addition to successive investment in June 2022, Evonik has partnered with the United States Government, by investing USD 220 million to build innovative drug delivery system for new lipid production facility for mRNA-based therapies.
The solution for a cost-effective purification process for proteins is frequently explored where the glutathione compound is linked to agarose beads with a suitable number of atom spacers that reduces the hindrance effect while undergoing purification. The innovation to develop such cost-effective compounds is accelerating and companies are conducting research in the field. Thermo Fisher Scientific Inc. has successfully developed pierce glutathione where the glutathione compound is linked to agarose beads through 12-atom spacer that substantially minimizes steric hinderance.
The company provides pierce glutathione agarose products in prepacked chromatography cartridges for delivering FPLC applications. The product delivers high performance and capacity properties for affinity purification of GST-tagged fusion proteins from cellular lysates. The pierce glutathione resin is economically priced and can be used five times without compromising purification performance and binding capacity which makes the product cost-effective. The product is clinically validated for its effective use with company's cell lysis reagents to extract and purify from mammalian or bacterial cell cultures.
Immune activity can be enhanced using nutritional or therapeutic composition while performing treatment of mammals. Glutathione precursor comprises of mixtures of glutamic acid, cystine, and glycine along with essential active ingredients like selenium. Selenium is a prominent trace metal found in various food compositions and is significantly incorporated in several non-toxic, water soluble organic or inorganic. Enhancement in cellular and tissue concentrations of glutathione improves resistance to infective agents by improving the immune system. Nutritional requirements are not fulfilled due to limited functionality of bacterial pathogens and commensals to metabolites. Hence, glutathione (GSH) is recognized as an abundant sulfur-content antioxidant present in mammalian tissues and is an incredible source of nutrient sulfur for human pathogens like staphylococcus aureus.
The data published by the Good Food Institute states that, in 2020 the United States market for plant-based foods is around USD 7.4 billion. Plant-based eggs are a modest category that is growing exponentially reaching around USD 39 million in 2021. The growing plant-based products are attracting various biological industries to improve nutritional characteristics which is subsequently creating market opportunities for glutathione resin market.
The outbreak of COVID-19 has severely impacted numerous sectors and human livelihood where every person was vulnerable to infectious disease. The shutdown of research laboratories accompanied by lower investment in pharmaceutical research has deteriorated the economic stability. But the urgency to develop effective drug to combat COVID-19 has created multiple opportunities for glutathione resin to incorporate rapid purification of glutathione-S-transferase (GST)-tagged recombinant proteins while reducing hinderance effect. The pandemic situation has created enormous potential for the market to expand and derive companies to incorporate services.
The glutathione resin market is successfully growing with the increasing demand for advanced and optimized protein purification process. Cytiva has developed Glutathione Sepharose 4B product which is an affinity chromatography resin for performing batch purification of glutathione-S-transferase (GST)-tagged proteins for attaining high binding capacity. The glutathione resin is chemically stable with all commonly used aqueous buffers and substantially used to study protein-protein interactions. Cytiva is successfully offering other life sciences solutions for undergoing purification GST fusion properties.
In October 2023, Cytiva and RoosterBio successively collaborated improving the exosome purification process for promising gene therapies and other significant modalities and manufacturing exosomes in mass quantities. The effective collaboration is developing prominent platform to provide cost-effective manufacturing solutions.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.